|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/519 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61K 31/55 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 31/55 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 3641775 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18731845.6 |
| Date of filing the European patent application | 2018-06-21 | |
| (97) | Date of publication of the European application | 2020-04-29 |
| (45) | Date of publication and mention of the grant of the patent | 2023-12-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2018/066551 |
| Date | 2018-06-21 |
| (87) | Number | WO 2018/234433 |
| Date | 2018-12-27 |
| (30) | Number | Date | Country code |
| 201762523389 P | 2017-06-22 | US | |
| 17189550 | 2017-09-06 | EP |
| (72) |
WEI, Andrew , AU
MOUJALLED, Donia , AU
POMILIO, Giovanna , AU
GENESTE, Olivier , FR
MARAGNO, Ana-Leticia , FR
|
| (73) |
Les Laboratoires Servier ,
35, rue de Verdun, 92284 Suresnes Cedex,
FR
Novartis AG , Lichtstrasse 35, 4056 Basel, CH |
| (54) | COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF |